Canadian Journal of Cardiology
Review| Volume 31, ISSUE 10, P1293-1302, October 2015

suPAR: A New Biomarker for Cardiovascular Disease?

Published:March 26, 2015DOI:


      The fundamental role of inflammation in cardiovascular disease (CVD) has prompted interest in numerous biomarkers that detect subclinical levels of inflammation. Soluble urokinase plasminogen activator receptor (suPAR) is a novel biomarker that correlates significantly with cardiovascular events and outperforms traditional markers of inflammation such as C-reactive protein (CRP) in prognosticating a range of CVDs. Furthermore, of particular interest is the suggestion that suPAR reflects a pathophysiological pathway more closely linked with subclinical organ damage than CRP. We provide the first comprehensive review of suPAR in CVD and explore its function and usefulness in predicting cardiovascular events.


      Le rôle fondamental de l’inflammation dans la maladie cardiovasculaire (MCV) a suscité l’intérêt pour de nombreux biomarqueurs qui détectent les degrés subcliniques d’inflammation. Le récepteur soluble de l’activateur du plasminogène de l’urokinase (suPAR : soluble urokinase plasminogen activator receptor) est un nouveau biomarqueur qui corrèle de façon significative avec les événements cardiovasculaires et surpasse les marqueurs traditionnels de l’inflammation tels que la protéine C réactive (CRP : C-reactive protein) dans le pronostic de nombreuses MCV. De plus, la suggestion selon laquelle le suPAR reflète une voie physiopathologique plus étroitement liée à la lésion subclinique de l’organe que le CRP revêt un intérêt particulier. Nous présentons la première étude exhaustive sur le suPAR dans les MCV, et explorons son fonctionnement et son utilité dans la prédiction des événements cardiovasculaires.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Ridker P.M.
        • Lüscher T.F.
        Anti-inflammatory therapies for cardiovascular disease.
        Eur Heart J. 2014; 35: 1782-1791
        • Lyngbæk S.
        • Marott J.L.
        • Sehestedt T.
        • et al.
        Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
        Int J Cardiol. 2013; 167: 2904-2911
        • Theilade S.
        • Lyngbaek S.
        • Hansen T.W.
        • et al.
        Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
        J Intern Med. 2014; 277: 1-10
        • Backes Y.
        • van der Sluijs K.F.
        • Mackie D.P.
        • et al.
        Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review.
        Intensive Care Med. 2012; 38: 1418-1428
        • Thunø M.
        • Macho B.
        • Eugen-Olsen J.
        suPAR: the molecular crystal ball.
        Dis Markers. 2009; 27: 157-172
        • Behrendt N.
        • Dano K.
        Effect of purified, soluble urokinase receptor on the plasminogen- prourokinase activation system.
        FEBS Lett. 1996; 393: 31-36
        • Blasia F.
        • Sidenius N.
        The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling.
        FEBS Lett. 2010; 584: 1923-1930
        • Smith H.W.
        • Marshall C.J.
        Regulation of cell signalling by uPAR.
        Nature Rev. 2010; 11: 23-36
        • Resnatil M.
        • Guttinger M.
        • Valcamonica S.
        • et al.
        Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
        EMBO J. 1996; 15: 1572-1582
        • Furlan F.
        • Orlando S.
        • Laudanna C.
        • et al.
        The soluble D2D3(88-274) fragment of the urokinase receptor inhibits monocyte chemotaxis and integrin-dependent cell adhesion.
        J Cell Sci. 2004; 117: 2909-2916
        • Steins M.B.
        • Padró T.
        • Schwaenen C.
        • et al.
        Overexpression of urokinase receptor and cell surface urokinase-type plasminogen activator in the human vessel wall with different types of atherosclerotic lesions.
        Blood Coagul Fibrinolysis. 2004; 15: 383-391
        • Tuomi H.
        • Kultti J.
        • Danielsson J.
        • et al.
        Serum soluble urokinase plasminogen activator receptor in alcoholics: relation to liver disease severity, fibrogenesis and alcohol use.
        J Gastroenterol Hepatol. 2014; 12: 1991-1995
        • Lyngbæk S.
        • Sehestedt T.
        • Marott J.L.
        • et al.
        CRP and suPAR are differently related to anthropometry and subclinical organ damage.
        Int J Cardiol. 2013; 167: 781-785
        • Eugen-Olsen J.
        • Andersen O.
        • Linneberg A.
        • et al.
        Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
        J Intern Med. 2010; 268: 296-308
        • Lyngbæk S.
        • Marott J.L.
        • Møller D.V.
        • et al.
        Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
        Am J Cardiol. 2012; 110: 1756-1763
        • Gozdzik W.
        • Adamik B.
        • Gozdzik A.
        • et al.
        Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.
        PLoS One. 2014; 9: e98923
        • Mekonnen G.
        • Corban M.T.
        • Hung O.Y.
        • et al.
        Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.
        Atherosclerosis. 2015; 239: 55-60
        • Khot U.N.
        • Khot M.B.
        • Bajzer C.T.
        • et al.
        Prevalence of conventional risk factors in patients with coronary heart disease.
        JAMA. 2003; 290: 898-904
        • Stoner L.
        • Lucero A.A.
        • Palmer B.R.
        • et al.
        Inflammatory biomarkers for predicting cardiovascular disease.
        Clin Biochem. 2013; 46: 1353-1371
        • Olsen M.H.
        • Sehestedt T.
        • Lyngbæk S.
        • et al.
        Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide—three new cardiovascular risk markers—do they improve risk prediction and influence treatment?.
        Curr Vasc Pharmacol. 2010; 8: 134-139
        • Hlatky M.A.
        • Greenland P.
        • Arnett D.K.
        • et al.
        Criteria for evaluation of novel markers of cardiovascular risk.
        Circulation. 2009; 119: 2408-2416
        • Pencina M.J.
        • D’Agostino R.B.
        • Vasan R.S.
        Statistical methods for assessment of added usefulness of new biomarkers.
        Clin Chem Lab Med. 2010; 48: 1703-1711
        • Jeppesen J.
        Low-grade chronic inflammation and vascular damage in patients with rheumatoid arthritis: don't forget 'metabolic inflammation'.
        J Rheumatol. 2011; 38: 595-597
        • Raman K.
        • Chong M.
        • Akhtar-Danesh G.G.
        • et al.
        Genetic markers of inflammation and their role in cardiovascular disease.
        Can J Cardiol. 2013; 29: 67-74
        • Sørensen M.H.
        • Gerke O.
        • Eugen-Olsen J.
        • et al.
        Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects.
        Atherosclerosis. 2014; 237: 60-66
        • Lindqvist M.
        • Wallinder J.
        • Henriksson A.E.
        Soluble urokinase plasminogen activator receptor in patients with abdominal aortic aneurysm.
        Thromb Res. 2012; 130: 511-551
        • McKie P.M.
        • Cataliotti A.
        • Sangaralingham S.J.
        • et al.
        Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year followup study.
        Mayo Clin Proc. 2011; 86: 1154-1160
        • Di Angelantonio E.
        • Chowdhury R.
        • Sarwar N.
        • et al.
        B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies.
        Circulation. 2009; 120: 2177-2187
        • Kruger R.
        • Schutte R.
        • Huisman H.W.
        • et al.
        NT-proBNP, C-reactive protein and soluble uPAR in a bi-ethnic male population: the SAfrEIC study.
        PLoS One. 2013; 8: e50506
        • Borné Y.
        • Persson M.
        • Melander O.
        • Smith J.G.
        • Engström G.
        Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation.
        Eur J Heart Fail. 2014; 16: 377-383
        • Matsushita K.
        • van der Velde M.
        • Astor B.C.
        • et al.
        Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.
        Lancet. 2010; 375: 2073-2081
        • Sehestedt T.
        • Lyngbæk S.
        • Eugen-Olsen J.
        • et al.
        Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events.
        Atherosclerosis. 2011; 216: 237-243
        • Persson M.
        • Engström G.
        • Björkbacka H.
        • Hedblad B.
        Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study.
        Atherosclerosis. 2012; 220: 502-505
      1. Botha S, Fouriea CMT, Schutte R, et al. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. Int J Cardiol 2015;

        • Eapen D.J.
        • Manocha P.
        • Ghasemzedah N.
        • et al.
        Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events.
        J Am Heart Assoc. 2014; 3: e001118
        • Lyngbæk S.
        • Andersson C.
        • Marott J.L.
        • et al.
        Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain.
        Clin Chem. 2013; 59: 1621-1629
        • Edsfeldt A.
        • Nitulescu M.
        • Grufman H.
        • et al.
        Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque.
        Stroke. 2012; 43: 3305-3312
        • Olson F.J.
        • Thurison T.
        • Ryndel M.
        • et al.
        Soluble urokinase-type plasminogen activator receptor forms in plasma as markers of atherosclerotic plaque vulnerability.
        Clin Biochem. 2010; 43: 124-130
        • Nakanishi K.
        • Fukuda S.
        • Shimada K.
        • et al.
        Impaired coronary flow reserve as a marker of microvascular dysfunction to predict long-term cardiovascular outcomes, acute coronary syndrome and the development of heart failure.
        Circ J. 2012; 76: 1958-1964
        • Bonapace S.
        • Rossi A.
        • Cicoira M.
        • et al.
        Increased aortic pulse wave velocity as measured by echocardiography is strongly associated with poor prognosis in patients with heart failure.
        J Am Soc Echocardiogr. 2013; 26: 714-720
        • Persson M.
        • Östling G.
        • Smith G.
        • et al.
        Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease.
        Stroke. 2014; 45: 18-23
        • Ridker P.M.
        • Danielson E.
        • Fonseca F.A.H.
        • et al.
        Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.
        Lancet. 2009; 373: 1175-1182
        • Asciutto G.
        • Edsfeldt A.
        • Dias N.V.
        • et al.
        Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques.
        Cardiovasc Pathol. 2013; 22: 438-443
        • Pawlak K.
        • Mysliwiec M.
        • Pawlak D.
        The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
        Thromb Res. 2008; 122: 328-335
        • Schutte A.E.
        • Myburgh A.
        • Olsen M.H.
        • Eugen-Olsen J.
        • Schutte R.
        Exploring soluble urokinase plasminogen activator receptor and its relationship with arterial stiffness in a bi-ethnic population: the SAfrEIC-study.
        Thromb Res. 2012; 130: 273-277
        • Meijers B.
        • Poesen R.
        • Claes K.
        • Dietrich R.
        Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease.
        Kidney Int. 2015; 87: 210-216
        • Pawlak K.
        • Pawlak D.
        • Mysliwiec M.
        Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
        Thromb Res. 2007; 120: 871-876
        • Botha S.
        • Fourie C.M.
        • Schutte R.
        • Kruger A.
        • Schutte A.E.
        Associations of suPAR with lifestyle and cardiometabolic risk factors.
        Eur J Clin Invest. 2014; 44: 619-626
        • Intzilakis T.
        • Hartmann G.
        • Mouridsen M.R.
        • et al.
        Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes.
        Eur J Clin Invest. 2013; 43: 457-468
        • Kjellman A.
        • Akre O.
        • Gustafsson O.
        • et al.
        Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening.
        J Intern Med. 2011; 269: 299-305
        • Booth R.A.
        • Hill S.A.
        • Don-Wauchope A.
        • et al.
        Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review.
        Heart Fail Rev. 2014; 19: 439-451
        • Portelli M.A.
        • Siedlinski M.
        • Stewart C.E.
        • et al.
        Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels.
        FASEB J. 2014; 28: 923-934
        • Zacho J.
        • Tybjaerg-Hansen A.
        • Jensen J.S.
        • et al.
        Genetically elevated C-reactive protein and ischemic vascular disease.
        N Engl J Med. 2008; 359: 1897-1908